Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in New-Onset Generalized Myasthenia Gravis
NCT06909214Phase 4Recruiting
- Sponsor
- argenx
- Start
- Apr 2025
- Primary completion
- Aug 2026
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoint: Minimal Symptom Expression at 16 weeks. Started Apr 2025; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06909214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909214.